Ok Biotech Co., Ltd.

As of June 30, 2026, Ok Biotech Co., Ltd. carries a market capitalization of 2.28B, placing it among publicly traded companies globally. Its enterprise value stands at 3.00B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Ok Biotech Co., Ltd.'s next confirmed earnings release is scheduled for November 17, 2026.

As of June 30, 2026, Ok Biotech Co., Ltd. has 135.99M shares outstanding.

As of June 30, 2026, Ok Biotech Co., Ltd. trades at a trailing price-to-earnings ratio of 9.57. The price-to-sales ratio is 1.51, and the price-to-book ratio stands at 0.91.

As of June 30, 2026, Ok Biotech Co., Ltd. trades at an EV/EBITDA multiple of 9.62 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.95 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 13.63 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Ok Biotech Co., Ltd. trades at an EV/FCF ratio of 11.20, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 3.00B versus a market cap of 2.28B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Ok Biotech Co., Ltd. maintains a current ratio of 2.40, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 40.56, indicating elevated leverage, while an interest coverage ratio of 31.64 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Ok Biotech Co., Ltd. posted a return on equity (ROE) of 9.90, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 5.54 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 6.32, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 6.72, useful for judging operating efficiency across full business cycles. The company generates approximately 16.71M in revenue per employee across its workforce of 92.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.25 indicates how many times Ok Biotech Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Ok Biotech Co., Ltd. recorded 34.95M in income tax expense. That works out to an effective tax rate of 11.92, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 293.10M, leaving 242.24M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Ok Biotech Co., Ltd.'s stock has gained approximately 3.85% over the past 52 weeks. The 50-day moving average sits at 16.34, while the 200-day moving average is 16.12.

Over the twelve months ended June 30, 2026, Ok Biotech Co., Ltd. generated 1.54B in revenue and converted that into 242.24M in net income, yielding earnings per share of 1.84. EBITDA reached 312.11M, while operating income came in at 169.23M.

As of June 30, 2026, Ok Biotech Co., Ltd. holds 382.88M in cash and equivalents against 1.04B in total debt, resulting in a net debt position of 572.28M. Total book value stands at 2.52B, with working capital of 801.56M providing operational flexibility.

Ok Biotech Co., Ltd. produced 491.18M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -231.89M in capital expenditures, free cash flow totaled 259.29M - equivalent to 1.88 per share.

Over the twelve months ended June 30, 2026, Ok Biotech Co., Ltd. posted a gross margin of 31.13, reflecting its pricing power and cost economics. The operating margin of 11.01 and net profit margin of 15.76 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Ok Biotech Co., Ltd. paid dividends of 0.00 per share. The dividend payout ratio of 0.00 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 11.03, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 3.22, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Ok Biotech Co., Ltd. shareholders.

Ok Biotech Co., Ltd.'s most recent stock split took place on October 7, 2026 with a 100000000:89631573 split ratio.

As of June 30, 2026, Ok Biotech Co., Ltd. has an Altman Z-Score of 1.89, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.